AngioDynamics (NASDAQ:ANGO) Updates FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of ($0.38)-($0.34) for the period, compared to the consensus EPS estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

Analyst Ratings Changes

Several research firms have recently commented on ANGO. Canaccord Genuity Group reduced their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a research note on Tuesday, December 10th.

AngioDynamics Stock Up 1.4 %

NASDAQ:ANGO opened at $9.40 on Wednesday. The company has a market cap of $381.96 million, a PE ratio of -1.54 and a beta of 0.59. The business’s 50 day moving average is $7.82 and its two-hundred day moving average is $7.27. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $9.63.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the business posted ($0.05) earnings per share. As a group, sell-side analysts expect that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.